205 related articles for article (PubMed ID: 27866064)
1. Incretin-based therapy for type 2 diabetes: A real class effect?
Savarese G; Lund LH; Rosano GMC
Int J Cardiol; 2017 Jan; 227():141-142. PubMed ID: 27866064
[No Abstract] [Full Text] [Related]
2. Novo Nordisk incretin and Cardiovascular Summit, Durban, June 2013.
Wagenaar P
Cardiovasc J Afr; 2013 Sep; 24(8):340. PubMed ID: 24240386
[No Abstract] [Full Text] [Related]
3. London buses: A cardiovascular outcome trial equivalent?
Grant PJ
Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
[No Abstract] [Full Text] [Related]
4. Incretins: cardiovascular safety and rationale for use.
Kok A
Cardiovasc J Afr; 2013 Mar; 24(2):46. PubMed ID: 23750348
[No Abstract] [Full Text] [Related]
5. [Incretin-based therapy in type 2 diabetes does not increase the risk of hospitalization for heart failure].
Steurer J
Praxis (Bern 1994); 2016 Jun; 105(13):785-6. PubMed ID: 27329712
[No Abstract] [Full Text] [Related]
6. Safety of incretin-based therapies for type 2 diabetes.
Davis TM
Med J Aust; 2011 Sep; 195(6):312-3. PubMed ID: 21929482
[No Abstract] [Full Text] [Related]
7. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
Roshanov PS; Dennis BB
Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials.
Mahmoud AN; Saad M; Mansoor H; Elgendy AY; Barakat AF; Abuzaid A; Mentias A; Elgendy IY
Int J Cardiol; 2017 Mar; 230():324-326. PubMed ID: 28043676
[No Abstract] [Full Text] [Related]
9. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
Wu S; Cipriani A; Yang Z; Yang J; Cai T; Xu Y; Quan X; Zhang Y; Chai S; Sun F; Zhan S
Expert Opin Drug Saf; 2018 Mar; 17(3):243-249. PubMed ID: 29320889
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials].
Avogaro A
G Ital Cardiol (Rome); 2016 Apr; 17(4):248-52. PubMed ID: 27093207
[TBL] [Abstract][Full Text] [Related]
12. Implications of incretin-based therapies on cardiovascular disease.
Rotz ME; Ganetsky VS; Sen S; Thomas TF
Int J Clin Pract; 2015 May; 69(5):531-49. PubMed ID: 25363540
[TBL] [Abstract][Full Text] [Related]
13. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
Olansky L
Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
[No Abstract] [Full Text] [Related]
14. Incretin therapy and its effect on body weight in patients with diabetes.
Lind M
Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
[TBL] [Abstract][Full Text] [Related]
15. New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?
Pagidipati NJ; Lopes RD
J Thorac Cardiovasc Surg; 2019 Oct; 158(4):1113-1117. PubMed ID: 31301898
[No Abstract] [Full Text] [Related]
16. Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies.
Addison D; Aguilar D
Curr Atheroscler Rep; 2011 Apr; 13(2):115-22. PubMed ID: 21170611
[TBL] [Abstract][Full Text] [Related]
17. [Incretins have changed and continue to change treatment strategy for type 2 diabetes].
Kvapil M
Vnitr Lek; 2011 Nov; 57(11):916-8. PubMed ID: 22165696
[TBL] [Abstract][Full Text] [Related]
18. [Anti-diabetic therapy and cardiovascular risk: the opportunity of incretin-based therapies. Introduction].
Mannucci E
G Ital Cardiol (Rome); 2013 Dec; 14(12 Suppl):3. PubMed ID: 24362780
[No Abstract] [Full Text] [Related]
19. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus.
Peters MN; Pollock JS; Rajagopalan S
J Diabetes Complications; 2016 Mar; 30(2):189-91. PubMed ID: 26632087
[No Abstract] [Full Text] [Related]
[Next] [New Search]
